Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to LP-284 for the treatment of soft tissue sarcomas. This is the third orphan designation for the LP-284 program and the sixth overall across Lantern's clinical pipeline. The designation marks a significant expansion of LP-284 beyond hematologic malignancies into solid tumors, reflecting its synthetic lethal mechanism that targets DNA repair deficiencies commonly found in adult soft tissue sarcomas.
Orphan Drug Designation is granted by the FDA to drugs intended for the treatment of rare diseases affecting fewer than 200,000 people in the United States. This designation provides benefits such as tax credits for clinical trial costs, waiver of FDA application fees, and seven years of market exclusivity upon approval. Lantern stated that this designation supports an accelerated regulatory pathway for LP-284 as the company continues its Phase 1 evaluation in B-cell non-Hodgkin lymphomas and advances development in additional rare cancer indications.
LP-284 is a novel small molecule designed to exploit vulnerabilities in cancer cells with defective DNA repair mechanisms. Soft tissue sarcomas are a diverse group of rare cancers that arise from connective tissues, and many subtypes exhibit DNA repair deficiencies, making them potential targets for LP-284's synthetic lethal approach. The expansion into solid tumors broadens the therapeutic potential of LP-284, which was initially being developed for hematologic cancers.
Lantern Pharma is a clinical-stage biotechnology company that leverages artificial intelligence, machine learning, and genomic data to streamline oncology drug development. The company's proprietary RADR AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design smarter clinical trials. Lantern's clinical-stage pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations.
The FDA's decision to grant Orphan Drug Designation for LP-284 in soft tissue sarcomas underscores the potential of Lantern's AI-driven approach to identify promising drug candidates for rare diseases with high unmet medical needs. As Lantern advances LP-284 through clinical development, this designation could facilitate more efficient regulatory interactions and provide a clearer path to approval for patients with limited treatment options.
For more details, the full press release is available at https://ibn.fm/6FcBo. Additional information about Lantern Pharma can be found in the company's newsroom at https://ibn.fm/LTRN.
